Session » Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 784

Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease

9:00AM-11:00AM: Abstract Number: 799

Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 790

Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?

9:00AM-11:00AM: Abstract Number: 802

Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 780

Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

9:00AM-11:00AM: Abstract Number: 797

Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 773

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation

9:00AM-11:00AM: Abstract Number: 791

Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 787

Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 800

Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience

9:00AM-11:00AM: Abstract Number: 775

Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin

9:00AM-11:00AM: Abstract Number: 798

Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model

9:00AM-11:00AM: Abstract Number: 783

Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients

9:00AM-11:00AM: Abstract Number: 786

Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 789

DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype

9:00AM-11:00AM: Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 803

Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment

9:00AM-11:00AM: Abstract Number: 774

Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 777

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

9:00AM-11:00AM: Abstract Number: 781

Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?

9:00AM-11:00AM: Abstract Number: 795

Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 778

Multiple Genetic Diagnoses in a Cohort of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)

9:00AM-11:00AM: Abstract Number: 794

Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 782

Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion

9:00AM-11:00AM: Abstract Number: 785

Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

9:00AM-11:00AM: Abstract Number: 801

Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing

9:00AM-11:00AM: Abstract Number: 793

Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients

9:00AM-11:00AM: Abstract Number: 792

Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 779

The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants

9:00AM-11:00AM: Abstract Number: 772

The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)

9:00AM-11:00AM: Abstract Number: 788

Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 796

Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 771

Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].